Minqi Luo1,2, Huan Liu1, Ke Zhuang1, Li Liu3, Bo Su1, Rongrong Yang2, Po Tien1, Linqi Zhang4, Xien Gui2, Zhiwei Chen3. 1. Modern Virology Research Center and AIDS Center, State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Hubei 430072, P.R. China. 2. †Zhongnan Hospital, Wuhan University, Wuhan 430071, China. 3. ‡ AIDS Institute, The University of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong SAR, P.R. China. 4. §AIDS Research Center, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100730, P.R. China.
Abstract
OBJECTIVE: To determine the prevalence of drug-resistant HIV-1 and the efficacy of first-line highly active antiretroviral therapy (HAART) regimens consisted of generic nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor among 339 study subjects in rural areas of Hubei province, China. METHODS: Two cross-sectional studies were conducted to investigate 150 HAART-naive (99 received subsequent therapy) between 2003 and 2005 and 288 HAART-experienced patients mainly between 2005 and 2006. Patients' CD4+ T-cell count and viral load were determined. HIV-1 pol gene fragments were amplified from patients' plasma by reverse transcriptase-polymerase chain reaction, subsequently sequenced and analyzed. RESULTS: About 83.5% of the patients were from rural villages. They were dominantly infected with subtype B' HIV-1 (96.7%) through paid blood donation (64.6%) and related blood transfusion (28.3%). We found that there was a steady increase of CD4 count over time among treated patients without detectable viral load (186/288, 64.6%). There was, however, an increasing prevalence of nucleoside reverse transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-resistant mutations among patients with detected viremia (102/288, 35.4%) after treatment for 3-6 (24.3%), 9-12 (57.1%), and 20-24 (63.3%) months, respectively. The increasing rates were associated with significant CD4 count drop and viral load increase. Some patients also developed multidrug-resistant mutants. CONCLUSIONS: : We report the first HIV-1 drug resistance study after 2 years on HAART among Chinese patients living in rural villages. Our data suggest that a significant portion of patients are failing first-line regimens with a trend of AIDS progression. It is therefore necessary to maximize the drug adherence and to make affordable second-line HAART regimens available immediately. Our results have implications for implementing HAART in underresourced developing country settings.
OBJECTIVE: To determine the prevalence of drug-resistant HIV-1 and the efficacy of first-line highly active antiretroviral therapy (HAART) regimens consisted of generic nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor among 339 study subjects in rural areas of Hubei province, China. METHODS: Two cross-sectional studies were conducted to investigate 150 HAART-naive (99 received subsequent therapy) between 2003 and 2005 and 288 HAART-experienced patients mainly between 2005 and 2006. Patients' CD4+ T-cell count and viral load were determined. HIV-1 pol gene fragments were amplified from patients' plasma by reverse transcriptase-polymerase chain reaction, subsequently sequenced and analyzed. RESULTS: About 83.5% of the patients were from rural villages. They were dominantly infected with subtype B' HIV-1 (96.7%) through paid blood donation (64.6%) and related blood transfusion (28.3%). We found that there was a steady increase of CD4 count over time among treated patients without detectable viral load (186/288, 64.6%). There was, however, an increasing prevalence of nucleoside reverse transcriptase inhibitor- and nonnucleoside reverse transcriptase inhibitor-resistant mutations among patients with detected viremia (102/288, 35.4%) after treatment for 3-6 (24.3%), 9-12 (57.1%), and 20-24 (63.3%) months, respectively. The increasing rates were associated with significant CD4 count drop and viral load increase. Some patients also developed multidrug-resistant mutants. CONCLUSIONS: : We report the first HIV-1 drug resistance study after 2 years on HAART among Chinese patients living in rural villages. Our data suggest that a significant portion of patients are failing first-line regimens with a trend of AIDS progression. It is therefore necessary to maximize the drug adherence and to make affordable second-line HAART regimens available immediately. Our results have implications for implementing HAART in underresourced developing country settings.
Authors: B Conway; M A Wainberg; D Hall; M Harris; P Reiss; D Cooper; S Vella; R Curry; P Robinson; J M Lange; J S Montaner Journal: AIDS Date: 2001-07-06 Impact factor: 4.177
Authors: Martin Markowitz; Hiroshi Mohri; Saurabh Mehandru; Anita Shet; Leslie Berry; Roopa Kalyanaraman; Alexandria Kim; Chris Chung; Patrick Jean-Pierre; Amir Horowitz; Melissa La Mar; Terri Wrin; Neil Parkin; Michael Poles; Christos Petropoulos; Michael Mullen; Daniel Boden; David D Ho Journal: Lancet Date: 2005 Mar 19-25 Impact factor: 79.321
Authors: Victoria A Johnson; Françoise Brun-Vézinet; Bonaventura Clotet; Huldrych F Günthard; Daniel R Kuritzkes; Deenan Pillay; Jonathan M Schapiro; Douglas D Richman Journal: Top HIV Med Date: 2007 Aug-Sep
Authors: Lisa A Spacek; Hasan M Shihab; Moses R Kamya; Doris Mwesigire; Allan Ronald; Harriet Mayanja; Richard D Moore; Michael Bates; Thomas C Quinn Journal: Clin Infect Dis Date: 2005-12-12 Impact factor: 9.079
Authors: Moses R Kamya; Harriet Mayanja-Kizza; Andrew Kambugu; Sabrina Bakeera-Kitaka; Fred Semitala; Patricia Mwebaze-Songa; Barbara Castelnuovo; Petra Schaefer; Lisa A Spacek; Anne F Gasasira; Elly Katabira; Robert Colebunders; Thomas C Quinn; Allan Ronald; David L Thomas; Adeodata Kekitiinwa Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: Hongtao Zhang; Francesca Curreli; Abdul A Waheed; Peter Y Mercredi; Mansi Mehta; Pallavi Bhargava; Daniel Scacalossi; Xiaohe Tong; Shawn Lee; Alan Cooper; Michael F Summers; Eric O Freed; Asim K Debnath Journal: Retrovirology Date: 2013-11-15 Impact factor: 4.602